| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-07 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-07 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-07 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-07 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.19 | 5e-07 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.29 | 6e-07 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.16 | 7e-07 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.16 | 9e-07 |